loading
Precedente Chiudi:
$0.729
Aprire:
$0.738
Volume 24 ore:
27,988
Relative Volume:
0.02
Capitalizzazione di mercato:
$4.40M
Reddito:
-
Utile/perdita netta:
$-11.27M
Rapporto P/E:
-0.0329
EPS:
-21.4132
Flusso di cassa netto:
$-9.40M
1 W Prestazione:
-12.91%
1M Prestazione:
-43.15%
6M Prestazione:
-54.81%
1 anno Prestazione:
-85.36%
Intervallo 1D:
Value
$0.693
$0.738
Intervallo di 1 settimana:
Value
$0.693
$0.8901
Portata 52W:
Value
$0.693
$6.171

Dermata Therapeutics Inc Stock (DRMA) Company Profile

Name
Nome
Dermata Therapeutics Inc
Name
Telefono
(858)-223-0882
Name
Indirizzo
3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO
Name
Dipendente
8
Name
Cinguettio
Name
Prossima data di guadagno
2024-08-15
Name
Ultimi documenti SEC
Name
DRMA's Discussions on Twitter

Confronta DRMA con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
DRMA
Dermata Therapeutics Inc
0.715 4.40M 0 -11.27M -9.40M -21.41
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.09 127.47B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
559.01 62.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
594.73 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
230.31 31.06B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
229.84 26.16B 3.81B -644.79M -669.77M -6.24

Dermata Therapeutics Inc Borsa (DRMA) Ultime notizie

pulisher
Apr 16, 2025

Dermata Therapeutics stock hits 52-week low at $0.7 By Investing.com - Investing.com South Africa

Apr 16, 2025
pulisher
Apr 16, 2025

Dermata Therapeutics stock hits 52-week low at $0.7 - Investing.com Australia

Apr 16, 2025
pulisher
Apr 15, 2025

Dermata reports early success in acne treatment with XYNGARI By Investing.com - Investing.com South Africa

Apr 15, 2025
pulisher
Apr 15, 2025

Dermata Therapeutics (DRMA) Reports Promising Phase 3 Trial Resu - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Dermata Therapeutics IncAnnounces Topline Results From Phase 3 Trial Of XyngariSEC Filing - marketscreener.com

Apr 15, 2025
pulisher
Apr 15, 2025

Dermata reports early success in acne treatment with XYNGARI - Investing.com

Apr 15, 2025
pulisher
Apr 15, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 15, 2025
pulisher
Apr 15, 2025

First-Ever Weekly Acne Treatment XYNGARI Achieves Major Phase 3 Success - Stock Titan

Apr 15, 2025
pulisher
Apr 15, 2025

Dermata Therapeutics, Inc. (NASDAQ:DRMA) Short Interest Up 307.9% in March - Defense World

Apr 15, 2025
pulisher
Apr 09, 2025

Dermata Therapeutics stock hits 52-week low at $0.79 By Investing.com - Investing.com Canada

Apr 09, 2025
pulisher
Apr 09, 2025

Dermata Therapeutics stock hits 52-week low at $0.79 - Investing.com

Apr 09, 2025
pulisher
Apr 04, 2025

Acne Vulgaris Market to Reach New Heights in Growth by 2034, - openPR.com

Apr 04, 2025
pulisher
Apr 01, 2025

Dermata Therapeutics stock hits 52-week low at $1 - Investing.com

Apr 01, 2025
pulisher
Mar 28, 2025

Dermata (DRMA) Initiates Warrant Exercise to Raise $6.2 Million - GuruFocus

Mar 28, 2025
pulisher
Mar 28, 2025

Biotech Stock Dermata Therapeutics, Inc. (Nasdaq: DRMA) Makes NASDAQ Top Gainer List on Positive Phase 3 Results - Investorideas.com

Mar 28, 2025
pulisher
Mar 28, 2025

12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga

Mar 28, 2025
pulisher
Mar 28, 2025

Why Braze Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - Benzinga

Mar 28, 2025
pulisher
Mar 28, 2025

Dermata Therapeutics (NASDAQ:DRMA) Shares Up 5.2% – Here’s What Happened - Defense World

Mar 28, 2025
pulisher
Mar 27, 2025

Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules - Yahoo Finance

Mar 27, 2025
pulisher
Mar 27, 2025

Dermata Raises Fresh $6.2M Capital: New Funding Fuels Clinical Pipeline Advancement - Stock Titan

Mar 27, 2025
pulisher
Mar 27, 2025

Gold Gains Over 1%; TD SYNNEX Shares Plunge After Downbeat Results - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

Nano-Cap Dermata Therapeutics Unveils Positive Data From Once Weekly Drug Study For Acne - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

Nasdaq Down Over 100 Points; US Initial Jobless Claims Fall - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

Pre-Market Momentum: Dermata Therapeutics (DRMA) Sees Sharp Gains - Stocks Telegraph

Mar 27, 2025
pulisher
Mar 27, 2025

XYNGARI shows promise in Phase 3 acne trial By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

Dermata shares rise on positive acne treatment trial results By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

Dermata shares rise on positive acne treatment trial results - Investing.com

Mar 27, 2025
pulisher
Mar 27, 2025

Dermata's XYNGARI(TM) Phase 3 Trial Topline Data Meets All Primary Endpoints - MarketScreener

Mar 27, 2025
pulisher
Mar 27, 2025

XYNGARI shows promise in Phase 3 acne trial - Investing.com

Mar 27, 2025
pulisher
Mar 27, 2025

First-Ever Weekly Acne Treatment XYNGARI Achieves Breakthrough in Phase 3 Trial - Stock Titan

Mar 27, 2025
pulisher
Mar 26, 2025

Dermata Therapeutics Faces Nasdaq Delisting Notice By Investing.com - Investing.com India

Mar 26, 2025
pulisher
Mar 25, 2025

Dermata Therapeutics Faces Nasdaq Delisting Notice - Investing.com

Mar 25, 2025
pulisher
Mar 17, 2025

Dermata Therapeutics, Inc. SEC 10-K Report - TradingView

Mar 17, 2025
pulisher
Mar 17, 2025

Major Catalyst Alert: Dermata's Phase 3 Acne Treatment Results Coming in Weeks - StockTitan

Mar 17, 2025
pulisher
Mar 12, 2025

Stocks Rally as US Consumer Prices Cool - The Globe and Mail

Mar 12, 2025
pulisher
Mar 12, 2025

Acne Market on Track for Major Expansion by 2032, According to DelveInsight | Clinuvel Pharma, Novan, Dermata Therapeutics, ioPharmX, Bausch Health Americas, Inc., Kintor Pharma, Sol-Gel Technologies - Barchart

Mar 12, 2025
pulisher
Mar 12, 2025

Acne Market on Track for Major Expansion by 2032, According - openPR

Mar 12, 2025
pulisher
Mar 11, 2025

Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne - openPR

Mar 11, 2025
pulisher
Mar 11, 2025

Tesla Stock is OversoldIs Now the Time to Be Brave? - The Globe and Mail

Mar 11, 2025
pulisher
Mar 10, 2025

Head-To-Head Analysis: Geron (NASDAQ:GERN) versus Dermata Therapeutics (NASDAQ:DRMA) - The AM Reporter

Mar 10, 2025
pulisher
Mar 10, 2025

Geron (NASDAQ:GERN) versus Dermata Therapeutics (NASDAQ:DRMA) Head-To-Head Comparison - Defense World

Mar 10, 2025
pulisher
Mar 04, 2025

Dermata Announces That Last Patient Completes Last Visit In Pivotal Xyngari Phase 3 Star-1 Clinical Trial For Acne - Marketscreener.com

Mar 04, 2025
pulisher
Mar 04, 2025

Dermata Therapeutics announces last patient visit in Phase 3 acne trial - TipRanks

Mar 04, 2025
pulisher
Mar 04, 2025

Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI™ Phase 3 STAR-1 Clinical Trial for Acne - PR Newswire

Mar 04, 2025
pulisher
Mar 03, 2025

Acne Market Predicted to See Upsurge Through 2032, Highlights - openPR

Mar 03, 2025
pulisher
Mar 03, 2025

Papulopustular Rosacea Clinical and Non-Clinical Studies, Key - openPR

Mar 03, 2025
pulisher
Mar 03, 2025

APO accepts Dermata’s patent application for DMT410 program for hyperhidrosis - MSN

Mar 03, 2025
pulisher
Feb 28, 2025

Ensysce Biosciences Stock Price, Quotes and Forecasts | NASDAQ:ENSC - Benzinga

Feb 28, 2025
pulisher
Feb 25, 2025

DRMADermata Therapeutics Inc Latest Stock News & Market Updates - StockTitan

Feb 25, 2025
pulisher
Feb 25, 2025

Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis - ACCESS Newswire

Feb 25, 2025

Dermata Therapeutics Inc Azioni (DRMA) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$19.85
price down icon 0.77%
$71.22
price down icon 2.53%
$32.51
price up icon 0.11%
$24.83
price down icon 0.47%
$97.38
price down icon 1.48%
biotechnology ONC
$231.14
price up icon 0.63%
Capitalizzazione:     |  Volume (24 ore):